AXGN logo

AXOGEN INC

AXGNNASDAQ
πŸ† #1467 by market capEarnings Nov 4US Equity
$630.67β–² $2.84 (+0.45%)
Simulated price
1hβ€”
24hβ–² 0.5%
7dβ–² 1294.1%
14dβ–² 1425.2%
30dβ–² 1496.0%
1yβ–² 4350.7%
🏦Market Cap
$2.59B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+23.6%
Healthy
πŸ“ŠGross Margin
74.6%
High
πŸ’΅FCF Margin
3.1%
Moderate
βš–οΈP/S Ratio
9.9x
Elevated
Otter Score
55
Weak

Trading Snapshot

Day Range
$624.37 – $637.73
52-Week Range
$13.64 – $48.72
Volume
$3.22B
Avg Volume
$2.23B
Shares Outstanding
53.8M
Next Earnings
Oct 17, 2026

Fundamentals Snapshot

Annual Revenue
$225M
Last Q Revenue
$70M
P/E Ratio
β€”
P/S Ratio
9.9x
EPS (TTM)
$-0.68
Dividend Yield
β€”

Why Investors Own AXGN

  • βœ“High-growth profile β€” revenue up +27.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 73% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$225Mβ–² +31.9% YoY
Gross Margin (TTM)
73.0%β–² +0.3% YoY
Operating Income (TTM)
$57Mβ–² +31.9% YoY
Free Cash Flow (TTM)
$67Mβ–² +31.9% YoY

About AXOGEN INC

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
55/100

Analyst Price Target

β“˜
Average Target
$621.49
β–Ό βˆ’1.5% Downside
High Target$681.13
Low Target$572.38
Based on 21 analysts

Latest News & Updates